Pharma News

China’s Luye Pharma has claimed its first FDA approval, getting a green light for Rykindo, an injectable formulation of the antipsychotic risperidone given every two weeks. ...

Scientists from The Australian National University (ANU) and the Peter MacCallum Cancer Centre have discovered that a protein, called Menin, contributes to abnormal deactivation of specific genes i...

Sanofi Ventures – focused on early-to-mid stage investing, company co-creation, leading financing rounds, and prioritising those companies advancing innovation – has announced an additional mul...

Cure Parkinson’s is delighted to announce that following promising results reported at phase 2 in 2020, a large-scale phase 3 clinical trial of ambroxol, a drug currently in use to treat respiratory...

The US Food and Drug Administration (FDA) has approved AstraZeneca and Avillion’s Airsupra (albuterol/budesonide), to treat asthma.

Biocon already produces a biosimilar copycat of Sanofi's Lantus. But its submission for its knockoff of Novo Nordisk's NovoLog has been hit with an FDA complete response letter.  ...

The FDA has approved Sanofi Pasteur’s supplemental biologics license application (sBLA) for  its Adacel vaccine to provide immunization during the third trimester of pregnancy to prevent per...

The biopsy test is the first companion diagnostic approved for entrectinib for individuals who do not have an available tissue sample.

BioMarin’s has signed the first contract with an insurer in Germany for Roctavian, its recently approved gene therapy for haemophilia A, as it tests out its outcomes-based agreement (OBA) reimbur...

AbbVie and Anima Biotech have announced that they are collaborating in a deal worth up to over $580 million to discover and develop drugs that modulate mRNA biology for three targets in cancer and...

The FDA has granted priority review to Roche’s biologics license application (BLA) for glofitamab for the treatment of adults with relapsed or resistant large B-cell lymphoma after two or more li...

Dutch biotech Synaffix has signed a $2 billion licensing agreement with Amgen to bring a new generation of antibody-drug conjugates (ADC) to market.